Top 12: Research in Systemic Lupus Erythematosus at a Glance

From 2000–05, Dr. Pisetsky served as editor of Arthritis & Rheumatism, and has been an associate editor of the Annals of the Rheumatic Diseases since 2012. He served as the president of the United States Bone and Joint Initiative from 2015–17.

References

1. Nakai T, Iwata F, Kidoguchi G, et al. Glucocorticoid discontinuation in patients with systemic lupus erythematosus with prior severe organ manifestation [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
2. So H, Chow E, Cheng I, et al. Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: The 6-month results of a randomized controlled trial [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
3. Petri M, Kallas R, Li J, et al. Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and clinical associations [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
4. Liao K, De Silva T, Bonin J. Ro positivity is an under‐recognised poor prognostic marker in systemic lupus erythematosus patients [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
5. Hasni S, Chapman M, Feng R, et al. A 12-week aerobic exercise training program in women with systemic lupus erythematosus (SLE) improves fatigue, mitochondrial dysfunction and associated interferon gene signature [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
6. Haj-Ali M, Deonaraine K, Engel A, et al. Lupus nephritis renal responses in relation to treatment and demographics: Observations from a multi-racial/ethnic cohort of 159 patients in the NYU Lupus Registry [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
7. Piranavan P, Perl A. Improvement of renal and non-renal SLE outcome measures on sirolimus therapy—a 21-year follow-up study of 73 patients [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
8. Munroe M, Lu R, Gross T, et al. Ability of soluble immune mediators and SLE-associated autoantibody specificities to forecast transition to classified SLE and inform a lupus classification risk immune index [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
9. Lieber S, Lipschultz R, Zahid S, et al. Association of telomere length with phenotypic frailty in systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
10. Becker Y, Gagné J, Julien A, et al. Identification of mitochondrial antigens targeted by autoantibodies in systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
11. Azzouz D, Chen Z, Li Z, et al. Disease flares in lupus are concordant with Ruminococcus blautia gnavus blooms within unstable gut microbiota communities [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
12. Raghunath S, Glikmann-Johnston Y, Guymer E, et al. Lack of association between cognitive test performance and cognitive symptoms in systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).